VKORC1 and congestive heart failure: Predicted analysis shows patients who have VKORC1 non-A genotypes but with acute kidney injury would have a significantly lower mean average daily dose than those without AKI (2.63 mg/day [95% CI 2.02–3.23] vs 3.80 mg/day [3.49–4.12], the value of other model cofactors: male, age 60 years, BSA 1.75 m2, no HTN, no CHF, serum albumin 40 g/L, CYP2C9 wild type).